Daxor Co. (NASDAQ:DXR – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totalling 14,800 shares, an increase of 39.6% from the August 31st total of 10,600 shares. Based on an average daily trading volume, of 4,000 shares, the days-to-cover ratio is presently 3.7 days. Approximately 0.7% of the company’s shares are short sold.
Wall Street Analyst Weigh In
Separately, Ascendiant Capital Markets upped their price objective on shares of Daxor from $24.50 to $24.75 and gave the company a “buy” rating in a report on Monday, September 9th.
Read Our Latest Stock Report on DXR
Daxor Stock Down 2.3 %
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
See Also
- Five stocks we like better than Daxor
- What is the S&P 500 and How It is Distinct from Other Indexes
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- CarMax’s Impressive Rally: What Investors Should Watch Next
- How to Plot Fibonacci Price Inflection Levels
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.